UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 3, 2004

ALEXION PHARMACEUTICALS, INC.

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Delaware (State or other jurisdiction

0-27756 (Commission File Number) 13-3648318 (IRS Employer

of incorporation)

Identification No.)

352 Knotter Drive, Cheshire, CT (Address of principal executive offices)

06410 (Zip Code)

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

Registrant s telephone number, including area code: (203) 272-2596

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

" Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b)) under the Exchange Act (17 CFR 240.14d-2(b))

" Pre-commencement communications pursuant to Rule 13e-4(g) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

Item 2	2.02	Results	of	Operations	and Financial	Condition.
--------	------	---------	----	-------------------	---------------	------------

On December 3, 2004, the Company announced its results of operations for its first fiscal quarter ended October 31, 2004. A copy of the press release issued by the Company relating thereto is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated December 3, 2004.

-2-

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: December 6, 2004 By: /s/ Thomas I. H. Dubin

Name: Thomas I. H. Dubin

Title: Vice President and General Counsel